Other formats:
BibTeX
LaTeX
RIS
@article{1218003,
author = {Skopalík, Josef and Polakova, Katerina and Havrdova, Marketa and Justan, Ivan and Magro, Massimiliano and Milde, David and Knopfová, Lucia and Šmarda, Jan and Poláková, Helena and Gabrielova, Eva and Vianello, Fabio and Michálek, Jaroslav and Zboril, Radek},
article_location = {Albany, New Zealnad},
article_number = {1},
doi = {http://dx.doi.org/10.2147/IJN.S66986},
keywords = {mesenchymal stromal cells; stem cell tracking; magnetic resonance imaging; superparamagnetic iron oxide nanoparticles; stem cell labeling},
language = {eng},
issn = {1178-2013},
journal = {International Journal of Nanomedicine},
title = {Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist - an initial in vitro study},
volume = {9},
year = {2014}
}
TY - JOUR
ID - 1218003
AU - Skopalík, Josef - Polakova, Katerina - Havrdova, Marketa - Justan, Ivan - Magro, Massimiliano - Milde, David - Knopfová, Lucia - Šmarda, Jan - Poláková, Helena - Gabrielova, Eva - Vianello, Fabio - Michálek, Jaroslav - Zboril, Radek
PY - 2014
TI - Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist - an initial in vitro study
JF - International Journal of Nanomedicine
VL - 9
IS - 1
SP - 5355-5372
EP - 5355-5372
PB - Dove Medical PRESS LTD
SN - 11782013
KW - mesenchymal stromal cells
KW - stem cell tracking
KW - magnetic resonance imaging
KW - superparamagnetic iron oxide nanoparticles
KW - stem cell labeling
N2 - Objective: Cell therapies have emerged as a promising approach in medicine. The basis of each therapy is the injection of 1-100x10(6) cells with regenerative potential into some part of the body. Mesenchymal stromal cells (MSCs) are the most used cell type in the cell therapy nowadays, but no gold standard for the labeling of the MSCs for magnetic resonance imaging (MRI) is available yet. This work evaluates our newly synthesized uncoated superparamagnetic maghemite nanoparticles (surface-active maghemite nanoparticles - SAMNs) as an MRI contrast intracellular probe usable in a clinical 1.5 T MRI system. Methods: MSCs from rat and human donors were isolated, and then incubated at different concentrations (10-200 mu g/mL) of SAMN maghemite nanoparticles for 48 hours. Viability, proliferation, and nanoparticle uptake efficiency were tested (using fluorescence microscopy, xCELLigence analysis, atomic absorption spectroscopy, and advanced microscopy techniques). Migration capacity, cluster of differentiation markers, effect of nanoparticles on long-term viability, contrast properties in MRI, and cocultivation of labeled cells with myocytes were also studied. Results: SAMNs do not affect MSC viability if the concentration does not exceed 100 mu g ferumoxide/mL, and this concentration does not alter their cell phenotype and long-term proliferation profile. After 48 hours of incubation, MSCs labeled with SAMNs show more than double the amount of iron per cell compared to Resovist-labeled cells, which correlates well with the better contrast properties of the SAMN cell sample in T2-weighted MRI. SAMN-labeled MSCs display strong adherence and excellent elasticity in a beating myocyte culture for a minimum of 7 days. Conclusion: Detailed in vitro tests and phantom tests on ex vivo tissue show that the new SAMNs are efficient MRI contrast agent probes with exclusive intracellular uptake and high biological safety.
ER -
SKOPALÍK, Josef, Katerina POLAKOVA, Marketa HAVRDOVA, Ivan JUSTAN, Massimiliano MAGRO, David MILDE, Lucia KNOPFOVÁ, Jan ŠMARDA, Helena POLÁKOVÁ, Eva GABRIELOVA, Fabio VIANELLO, Jaroslav MICHÁLEK and Radek ZBORIL. Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist - an initial in vitro study. \textit{International Journal of Nanomedicine}. Albany, New Zealnad: Dove Medical PRESS LTD, 2014, vol.~9, No~1, p.~5355-5372. ISSN~1178-2013. Available from: https://dx.doi.org/10.2147/IJN.S66986.
|
